세계의 종양학 분야 인공지능 시장

Global Artificial Intelligence in Oncology Market to Reach US$16.3 Billion by 2030

The global market for Artificial Intelligence in Oncology estimated at US$3.9 Billion in the year 2024, is expected to reach US$16.3 Billion by 2030, growing at a CAGR of 26.9% over the analysis period 2024-2030. Hardware Component, one of the segments analyzed in the report, is expected to record a 24.3% CAGR and reach US$5.7 Billion by the end of the analysis period. Growth in the Software Component segment is estimated at 30.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 25.7% CAGR

The Artificial Intelligence in Oncology market in the U.S. is estimated at US$1.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 25.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 24.2% and 23.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 18.9% CAGR.

Global Artificial Intelligence in Oncology Market - Key Trends & Drivers Summarized

How Is AI Revolutionizing Cancer Diagnosis and Treatment?

Artificial Intelligence (AI) is transforming oncology by enabling earlier diagnosis, personalized treatment planning, and enhanced patient monitoring. Traditional cancer care often involves complex decision-making processes and labor-intensive workflows. AI addresses these challenges by leveraging machine learning (ML) algorithms, predictive analytics, and natural language processing (NLP) to analyze vast datasets and provide actionable insights.

In diagnostics, AI-powered imaging tools are revolutionizing cancer detection by analyzing radiology images, such as CT scans and MRIs, with unparalleled accuracy. These systems can identify subtle patterns indicative of malignancies, facilitating early detection and improving treatment outcomes. For instance, AI has demonstrated the ability to detect breast and lung cancers at earlier stages, reducing mortality rates significantly.

AI is also enhancing treatment planning by analyzing patient-specific data, including genetic profiles and tumor characteristics, to recommend personalized therapies. Predictive models evaluate the likely efficacy of treatments, enabling oncologists to make data-driven decisions. Additionally, AI systems assist in monitoring treatment progress and identifying potential side effects, ensuring that interventions are adjusted promptly to optimize patient care.

What Drives the Adoption of AI in Oncology?

The increasing prevalence of cancer and the urgent need for advanced diagnostic and treatment solutions are significant drivers of AI adoption in oncology. Cancer remains one of the leading causes of death globally, creating a critical demand for technologies that can improve early detection and enhance patient outcomes. AI tools provide healthcare professionals with the precision and efficiency required to meet these challenges.

The rise of precision medicine is another key factor. As cancer therapies become more targeted and personalized, AI is playing a pivotal role in analyzing complex datasets, such as genomic and proteomic information, to identify tailored treatment options. This capability is transforming oncology care, shifting the focus from one-size-fits-all approaches to individualized treatment strategies.

Furthermore, advancements in wearable devices and remote monitoring technologies are expanding the applications of AI in oncology. These tools generate real-time patient data, enabling continuous monitoring of symptoms and treatment responses. AI systems analyze this data to detect complications early and provide recommendations for proactive management, ensuring better outcomes for patients.

Can AI Improve Accessibility and Efficiency in Oncology Care?

AI is significantly enhancing accessibility and efficiency in oncology care by automating processes and enabling remote diagnostics. In regions with limited access to specialized oncologists, AI-powered tools bridge the gap by providing diagnostic support and treatment recommendations. Telemedicine platforms integrated with AI enable patients to receive expert consultations without traveling long distances, improving access to quality care.

AI also optimizes workflows in oncology departments by automating time-consuming tasks such as imaging analysis, pathology slide interpretation, and clinical documentation. This efficiency reduces the workload on healthcare providers, allowing them to focus on patient care. Additionally, AI systems prioritize high-risk cases, ensuring that patients requiring immediate attention are identified and treated promptly.

By enhancing the accuracy and speed of cancer diagnostics, AI minimizes delays in treatment initiation, a critical factor in improving survival rates. These advancements make oncology care more efficient and accessible, addressing disparities in cancer treatment and outcomes.

What’s Driving the Growth of the AI in Oncology Market?

The growth in the Artificial Intelligence in Oncology market is driven by several critical factors, reflecting its transformative potential in cancer care. The increasing availability of high-quality data, including medical images, patient records, and genomic profiles, is providing a foundation for AI-powered oncology solutions. These tools leverage data to improve diagnostic accuracy, personalize treatments, and monitor outcomes effectively.

Consumer behavior trends, such as the demand for proactive health management and personalized care, are encouraging healthcare providers to adopt AI technologies. Patients are seeking innovative solutions that enhance their treatment experiences and outcomes, driving investments in AI-powered oncology tools.

Additionally, regulatory support for AI-based medical devices and increasing investments in oncology research are fueling market growth. Governments and healthcare organizations are promoting the adoption of AI to improve cancer care delivery and reduce healthcare costs. These factors, combined with ongoing advancements in AI algorithms and hardware, are propelling the rapid expansion of the AI in Oncology market, positioning it as a cornerstone of future innovation in cancer diagnostics and treatment.

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence in Oncology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Hardware Component, Software Component, Services Component); Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Other Cancer Types); Application (Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application, Immunotherapy Application); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

• Azra AI
• ConcertAI LLC
• GE Healthcare
• IBM Corporation
• Intel Corporation
• Median Technologies
• Mercurius Health
• NVIDIA Corporation
• Quest Diagnostics, Inc.
• Siemens Healthineers AG

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Economic Frontiers: Trends, Trials & Transformations
  • Artificial Intelligence in Oncology - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • AI-Driven Cancer Diagnostics Propel Growth in Early Detection and Screening Markets
  • Integration of AI in Tumor Genomics Expands Opportunities in Precision Oncology
  • AI Models for Treatment Planning Strengthen Business Case for Personalized Cancer Care
  • Demand for AI in Immunotherapy Research Spurs Innovation in Drug Development
  • Advancements in AI-Powered Radiology Expand Addressable Market for Imaging-Guided Therapies
  • AI in Clinical Trial Matching Highlights Opportunities for Accelerating Oncology Research
  • AI Tools for Predictive Outcome Analysis Propel Growth in Clinical Decision Support Systems
  • Real-Time AI Insights in Radiation Therapy Optimize Dose Delivery, Enhancing Patient Outcomes
  • AI in Liquid Biopsy Analysis Sets the Stage for Non-Invasive Cancer Screening
  • AI Models for Cancer Recurrence Prediction Highlight Opportunities in Survivorship Care
  • Demand for AI-Powered Decision-Making Tools Drives Adoption in Comprehensive Cancer Centers
  • AI in Palliative Care Solutions Expands Market for Holistic Oncology Management
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Artificial Intelligence in Oncology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Artificial Intelligence in Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Hardware Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Hardware Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Software Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Software Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Services Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Services Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Diagnostics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Radiation Therapy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Radiation Therapy Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Research & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Research & Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Chemotherapy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Chemotherapy Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Immunotherapy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Immunotherapy Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World 6-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 23: World 6-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 24: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 25: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World 6-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 29: World 6-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 30: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 31: World 6-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World 6-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 34: World Recent Past, Current & Future Analysis for Brain Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 35: World 6-Year Perspective for Brain Tumor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 36: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 37: World 6-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Artificial Intelligence in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
  • TABLE 40: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 41: USA 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
  • TABLE 42: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 43: USA 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
• CANADA
  • TABLE 46: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: Canada 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
  • TABLE 48: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 49: Canada 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 52: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 53: Canada 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
• JAPAN
  • Artificial Intelligence in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 54: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 55: Japan 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
  • TABLE 58: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: Japan 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 60: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: Japan 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
• CHINA
  • Artificial Intelligence in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
  • TABLE 64: China Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 65: China 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
  • TABLE 66: China Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 67: China 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
• EUROPE
  • Artificial Intelligence in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 70: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 71: Europe 6-Year Perspective for Artificial Intelligence in Oncology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 72: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 73: Europe 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
  • TABLE 76: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 77: Europe 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 78: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 79: Europe 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
• FRANCE
  • Artificial Intelligence in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
  • TABLE 82: France Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 83: France 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
  • TABLE 84: France Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 85: France 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
• GERMANY
  • Artificial Intelligence in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 88: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Germany 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
  • TABLE 90: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Germany 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 94: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 95: Germany 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
• ITALY
  • TABLE 96: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 97: Italy 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
  • TABLE 100: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 101: Italy 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 102: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 103: Italy 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
• UNITED KINGDOM
  • Artificial Intelligence in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 104: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
  • TABLE 106: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 107: UK 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
  • TABLE 108: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 109: UK 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 113: Rest of Europe 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
  • TABLE 114: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 115: Rest of Europe 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
  • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Rest of Europe 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 119: Rest of Europe 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
• ASIA-PACIFIC
  • Artificial Intelligence in Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 121: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
  • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
  • TABLE 124: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 125: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 126: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 127: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Component - Hardware Component, Software Component and Services Component - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Rest of World 6-Year Perspective for Artificial Intelligence in Oncology by Component - Percentage Breakdown of Value Sales for Hardware Component, Software Component and Services Component for the Years 2025 & 2030
  • TABLE 130: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Application - Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 131: Rest of World 6-Year Perspective for Artificial Intelligence in Oncology by Application - Percentage Breakdown of Value Sales for Diagnostics Application, Radiation Therapy Application, Research & Development Application, Chemotherapy Application and Immunotherapy Application for the Years 2025 & 2030
  • TABLE 132: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 133: Rest of World 6-Year Perspective for Artificial Intelligence in Oncology by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Oncology by Cancer Type - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of World 6-Year Perspective for Artificial Intelligence in Oncology by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor and Other Cancer Types for the Years 2025 & 2030

IV. COMPETITION